JMI Laboratories

Advancing antimicrobial therapies worldwide through outstanding science

[JMI Laboratories @jmilabs]

@OncIDPharmd Finlandograms and MIC distribution histograms are back!
Thanks for your patience and the interest in the SENTRY program. https://t.co/1aUAVw5D9g

[BSAC @BSACandJAC]

"The potent in vitro activity of sulopenem against this large collection of recent Enterobacterales and anaerobic clinical isolates from various infection types support its further clinical evaluation to treat IAIs and UTIs"

https://t.co/Dj0Tv8c9nr
@jmilabs #OpenAccess #JACNews

[JMI Laboratories @jmilabs]

#ECCMID2023 might have ended, but you can still access our posters on our website:

https://t.co/YkT0Sc5EJa

[bioMérieux @biomerieux]

🤝 We are entering into a 6-year collaboration with @jmilabs to undertake to evaluate the performance and increasing potential of rapid and innovative microbiology diagnostics as important tools in the battle against #AMR.

Read more: https://t.co/x9SazCfBqL

@ElementTesting

[Element Materials Technology @ElementTesting]

Congratulations to our team at @jmilabs who are partnering with @biomerieux to fight #antimicrobial resistance. 🦠

Read more here: https://t.co/2FYBeANgkx

[JMI Laboratories @jmilabs]

Interesting!

[Mirage News @MirageNewsCom]

New Wound Dressing Reveals Infection
#Sweden
https://t.co/ffbCGM9lwB

[JMI Laboratories @jmilabs]

We're looking forward to seeing you soon at #ECCMID2023!

[Pattern Bioscience @Patternbio]

The process of naming bacteria follows specific rules – but do you know what they are? Fun Friday read from @IDTransmission

https://t.co/VRlRkJdv5c

#infectiousdiseases #pathology #microbiology #scicomms #IDTwitter

[JAC-AMR @jac_amr]

“Aztreonam/avibactam activity was not adversely affected by clinically relevant CPEs. Our results support aztreonam/avibactam development to treat infections caused by CRE, including MBL producers”

https://t.co/SBDWKOiT8G
@jmilabs @heliosader #JACAMRNews

[Matt Davis @MattDavis138]

Just discovered the @jmilabs SENTRY database’s public-facing page (late to the party, I know).

This is SO COOL for looking at resistance rates/patterns! Can also do granular queries for specific genes/phenotypes/bugs/etc.

https://t.co/JWOg4gitDo

[JMI Laboratories @jmilabs]

In Q1 2023, we published 12 peer-review articles.

Read them here: https://t.co/NCdoDXPcfp

[JMI Laboratories @jmilabs]

@AMAManual Much appreciated!

[JMI Laboratories @jmilabs]

Have you reviewed the late 2022 @WHO's fungal priority pathogens list? https://t.co/v3izY3FtMG

[JMI Laboratories @jmilabs]

.@AMAManual, do you have an official designation for which countries fall into Eastern vs. Western Europe? And, if so, how was this divided? By WHO regulations or something else?

[JMI Laboratories @jmilabs]

Drug-resistant fungal infections increased according to @sciam: https://t.co/H70hu0Dbdu

[JMI Laboratories @jmilabs]

Congratulations to @MundipharmaTalk on their FDA approval for rezafungin (rezzayo)!

https://t.co/XqtS2KVNXD

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

Over 800 registrations! 🤩
Many thanks to all the participants for this amazing webinar.

Recording now available 👇
https://t.co/odWTL5P5MP

@jmilabs @RafaMCanton @microRyC

#antibacterialdrug #webinar

[IDWeek @IDWeekmtg]

Fellows in-training, residents and medical students are invited to present cases at #IDWeek2023. Selected cases will be featured in Fellows’ Day workshops, and travel grants up to $800 are available to cover expenses.

Submit your case by May 3: https://t.co/X3v1aWPrUZ

[JMI Laboratories @jmilabs]

We're happy to share the completion of our 2022 SENTRY Antimicrobial Surveillance Testing!

[Matt Davis @MattDavis138]

Incredibly informative report from the team at @jmilabs on longitudinal (2016-2020) resistance patterns in E. coli and K. pneumo.

Lots of pertinent info but a few things that stood out:

Link: https://t.co/NIPvMf5JuR